Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07670377 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 Years

StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Eligibility criteria expanded, about 46 words
    • Secondary endpoints: details revised at 7 of 16 entries
    • Site details revised
  2. Recruitment opened
    • Study sites: 0 to 1
    • Primary completion date: Aug 27, 2026 to Aug 24, 2026
    • Study completion date: Aug 31, 2026 to Aug 24, 2026
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GlaxoSmithKline
246 trials monitored
See 20 trials at risk
This study aims to evaluate whether GSK3772701 alters the pharmacokinetics (PK) of midazolam (MDZ), a standard probe substrate for the CYP3A4 enzyme. The findings are planned to be used to determine whether GSK3772701 acts as an inducer and/or inhibitor of CYP3A4 and will help guide recommendations for safe co-administration with CYP3A4 substrates.
Trial Details
NCT Number NCT07670377
Lead Sponsor GlaxoSmithKline
Conditions
(from sponsor)		 Malaria, Falciparum
Related terms Malaria, Falciparum
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov